A flexible portfolio of in vitro transcription solutions generating high yield mRNA

In vitro transcription (IVT) is a common and convenient method that is critical for mRNA synthesis and RNA research.

Our Invitrogen mMessage mMachine and MEGAscript kits are the most competent kits in the industry when it comes to flexibility in producing synthetic mRNA via in vitro transcription. Invitrogen offers a unique and proven suite of products that meet critical process, scale, and quality to accelerate your mRNA discovery. This includes downstream applications, such as mRNA vaccines for infectious diseases and mRNA therapeutics for rare disease, antibody therapy, and protein therapy.

The very first in vitro transcription kits, mMessage mMachine and MEGAscript, were commercialized in 1989 under Ambion, now known as Invitrogen. While the brand has evolved, the quality and superior results remain the same. With over 50,000 citations, these kits are recognized as the most reliable and high-performing solutions in the industry, with the capability to overcome a variety of limitations with flexible offerings for synthesizing RNA.

With a variety of polymerases to choose from (T7, SP6, and T3) to transcribe a linearized DNA template or PCR-amplified DNA into mRNA, we offer a series of kits to fit your research needs. Our MEGAscript and mMessage mMachine kits allow for synthetic mRNA to be customizable with the ability to modify nucleotides, polymerases, Poly(A) Tailing Kit, and capping technologies (mCap analog, ARCA), to synthesize custom mRNA and accelerate your mRNA discovery. See our most popular in vitro transcription T7 polymerase kits below.


In vitro transcription kits selection guide

 



MEGAscript T7
Transcription Kit Plus



mMessage mMachine T7
Transcription Kit



mMessage mMachine T7
Transcription mRNA Kit with CleanCap Reagent AG



mMessage mMachine T7
Ultra Transcription Kit

DescriptionNext generation in vitro transcription kit for uncapped mRNA synthesisFirst generation mCap analog for capped mRNA synthesisOffers third generation cap (natural cap found in humans) CleanCap® Reagent AGDesign offers second generation ARCA cap for mRNA synthesis
Benefits
  • Provides the most flexibility by allowing researchers to add their own capping technology, modified nucleotides, and poly(A) tail insertions
  • Offers robust performance generating high yields
  • Optimized protocol provided for ease of use
  • Designed with TheraPure components to enable easy transition to mRNA development
  • Offers an enzyme mix for optimized IVT reactions
  • Allows researchers to use traditional m7cap analog and incorporate their own poly(A) tail
  • Optimized protocol provided for ease of use
  • Provides TheraPure reagents coupled with CleanCap® reagent AG for most optimal co-transcriptional mRNA synthesis
  • Allows researchers flexibility to add their own modified nucleotides and poly(A) tail
  • Optimized protocol provided for ease of use
  • Allows easy transition to TheraPure GMP components
  • Our most inclusive kit
  • Provides researchers access to ARCA cap analog and poly(A) tail in a single kit
  • Optimized protocol provided for ease of use
Capping efficiencyN/A70–80%≥95%70–80%
Yield per reaction100 µg20–30 µg≥100 µg20–30 µg
Scalability+++++++++++++
megaclear-kit-2

MEGAclear Transcription Clean-Up Kit

A simple solution for RNA clean-up plus purification after in vitro transcription and other enzymatic reactions. The kit contains silica spin column solutions that efficiently separate RNA from unincorporated NTPs, enzymes, and buffer components.

Learn more

Scientist

Interested in outsourcing?

Consider our custom mRNA Synthesis Services which utilize our best-in-class in vitro transcription products and team of experts to help streamline your workflow.


Learn more


Explore performance data for our newest kit with CleanCap® technology

Graph of mRNA yield

Figure 1. The mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG can give mRNA yields >5 mg/mL or >100 µg for a standard 20 µL reaction. The kit can give 5 times more mRNA than the mMessage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog, and 1.5 times more mRNA than a leading competitor mRNA kit with CleanCap® Reagent AG. The gray bars in the plot are the average yields for 5 different templates with the different IVT kits. The different color dots indicate the average mRNA yields for each template. Green: GFP (1 kb long). Blue: Cas9 (5 kb long). Orange: Gaussia luciferase (0.8 kb long). Yellow: Firefly luciferase (2 kb long). Black: VEE self-amplifying GFP (10 kb long). Three replicates were performed for each template with each mRNA kit.

Graph of mRNA performance

Figure 2. mRNA made by the mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG can have significantly higher cell performance than mRNA made by the mMesage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog and is on par with a leading competitor mRNA kit with CleanCap Reagent AG. For this experiment, fLuc mRNA was made by each of the mRNA kits, and 25 ng of the mRNAs were transfected into A549 human lung carcinoma epithelial cells using the Lipofectamine MessengerMAX Transfection Reagent. Cell were assayed 24 hours later for luciferase activity using the Pierce Firefly Luc One-Step Glow Assay Kit.

Graph of mRNA capping efficiency

Figure 3. The mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG can have mRNA capping efficiencies >95%. This is significantly higher than the mMessage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog, and is on par with a leading competitor mRNA kit with CleanCap® Reagent AG. Average capping efficiencies were calculated from 5 different templates.

Graph of mRNA quality

Figure 4. The mMessage mMachine T7 mRNA Kit with CleanCap® Reagent AG gives mRNA qualities similar to the mMessage mMachine T7 Ultra Transcription Kit that has the ARCA cap analog and a leading competitor mRNA kit with CleanCap® Reagent AG. The agarose gels for 5 different mRNAs show that the qualities are similar for all three kits.

Application note: Generating high-quality mRNA for in vivo delivery

Download the application note to learn more about how our mMESSAGE mMACHINE T7 mRNA Kit with CleanCap® Reagent AG works with lipid nanoparticle (LNP) technology for effective in vivo delivery of mRNA.
Download now

 

CAR T Cells Mend Broken Mouse Hearts

Learn how our MEGAscript kit was used to develop CAR T therapy targeting fibrosis

saRNA vaccines

Evaluate the role of in vitro transcription in the development of novel oral vaccines utilizing self-amplifying RNA (saRNA)

Support

 

For Research Use Only. Not for use in diagnostic procedures.